Alliance Boosts Drug Discovery Service

Dijon-based biopharmaceutical company Oncodesign has formed a new strategic alliance with Chinese biotech HitGen, enabling the combined complementary technology of both partners to more efficiently identify novel hits for challenging biological targets. The French company’s Integrated Drug Discovery Service (IDDS) offer, known as DRIVE™ has also been strengthened and deepened through the collaboration.
The two companies have built a joint value proposition where HitGen applies its powerful DNA Encoded Library (DEL) technology platform to identify tractable hits and Oncodesign’s DRIVE can quickly assess newly synthesized compounds within a collaborative environment between medicinal chemists, in vitro/in vivo pharmacologists and DMPK specialists.
“As a result of this new alliance, Oncodesign’s clients will be able to leverage the benefits from both our drug discovery expertise and HitGen’s DEL technology platform in major therapeutic areas,” said Fabrice Viviani, senior executive vice president and chief of Oncodesign’s Service Business Unit. “We are confident that the quality of the starting hits generated by HitGen will impact the future likelihood of success of the preclinical candidates delivered by Oncodesign.”